Thoughts Leading Up To #BIO2017
#BIO2017 is days away. What can we expect? Crowded Partnering - By our unofficial count, the number of companies registered for One-on-One Partnering exceeds the number from San…
Menu
What is your Acceptance Rate?
An Acceptance Rate is simply the percentage of meeting requests which are accepted at a given conference. At Lacerta Bio, we have been tracking Acceptance Rates for conferences since…
NSAIDs: More Bad News
NSAIDs are an $11-12+ billion market, yet the problems with these drugs continue to make headlines. The most recent study examined data from nearly 450,000 patients, and concluded (our…
Control or Collaboration – Value Creation & Success Focus
The following commentary is from Mr. Tom Brya, Managing Director at Titenare GXL. Titenare is an international consultancy providing integrated, knowledge-based services and solutions to pharma companies internationally. For further…
Biosimilars: Who wants to play this game?
A recent post by Robert Wessman of Alvogen pointed out that some companies are abandoning their efforts in the biosimilars markets. Amgen, for instance, recently decided to postpone…
Visit to England: What Did We Learn?
We just returned from a brief trip to England, where we met with a client, plus a few friends and colleagues. Over several meetings and meals, three issues consistently came…
Drug Overdose Deaths: What Can Pharma Do?
Last week, the US Centers for Disease Control published a rather alarming report on drug overdose deaths in the US. Here are a few items which we found…
When Does BIO Start?
BIO starts in June, right? Wrong. Perhaps BIO starts in late April, when partnering opens? Sorry. Wrong again. BIO started the moment you decided to…
What is Digital Health?
We recently learned about Bayer's Grants4Apps program. This program provides support to companies and projects involving "...novel software, hardware, technologies...contributing to improve health outcomes or pharmaceutical processes." Bayer is…
Is My Asset Licensable?
This is a good question...a question which lacks a simple answer without quite a bit of analysis. We audit out-licensing processes, and there are times when the answer is…
- Go to the previous page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- …
- 33
- Go to the next page